Abstract
Fatty acid binding protein 5 (FABP5) is elevated in psoriatic keratinocytes and could be involved in systemic metabolic disturbances in psoriasis. The aim of the study was to evaluate serum FABP5 in obese and non-obese psoriatic patients, to assess the relationship between FABP5 and the duration, severity of the disease, inflammatory and metabolic markers and influence of treatment with narrowband—ultraviolet B (NB-UVB). Seventy-four patients (30 treated with NB-UVB) with psoriasis were enrolled in the study. The serum concentrations of FABP5 were measured using Human FABP5 Enzyme-Linked Immunosorbent Assay kit. Serum fatty acids were measured by gas–liquid chromatography. Serum FABP5 levels in psoriatic patients were higher versus control group (P < 0.001). FABP5 in patients with PASI > 20 was higher compared to the mild group (PASI < 10) (P < 0.001) and serum FABP5 correlated positively with PASI score (r = 0.41, P < 0.001). There was also positive correlation between FABP5 and basic inflammation indices. Decrease of PASI after NB-UVB treatment (P < 0.001) was observed and accompanied by decrease of the serum FABP5 (P = 0.007). FABP5 is a potential marker of psoriasis, its severity and clinical outcome after therapy with NB-UVB. FABP5 may reflect metabolic disturbances in psoriatic patients.
Highlights
Psoriasis is an immune-mediated, chronic inflammatory skin disease of complex patomechanism
Several studies have shown that psoriasis is associated with systemic disorders specially metabolic syndrome (MS), which is defined as a constellation of insulin resistance, obesity, hyperlipidemia and hypertension [1, 2] Psoriatic patients are predisposed to other comorbidities like: inflammatory bowel diseases, cardiovascular diseases and non-alcoholic fatty liver disease (NAFLD) [3,4,5]
These findings may suggest that serum concentration of Fatty acid binding protein 5 (FABP5) could be used as a novel clinical biomarker of inflammation and disease severity in psoriasis
Summary
Psoriasis is an immune-mediated, chronic inflammatory skin disease of complex patomechanism. Several studies have shown that psoriasis is associated with systemic disorders specially metabolic syndrome (MS), which is defined as a constellation of insulin resistance, obesity, hyperlipidemia and hypertension [1, 2] Psoriatic patients are predisposed to other comorbidities like: inflammatory bowel diseases, cardiovascular diseases and non-alcoholic fatty liver disease (NAFLD) [3,4,5]. A number of proteins facilitating fatty acid transport, including fatty acid binding protein (FABP) have been identified. These proteins, do buffer lipids, and are crucial mediators of metabolic and other biological activities [10]. Fatty acid binding protein 5 (FABP5, or Epidermal Fatty Acid Binding Protein, E-FABP) is a lipid carrier, originally
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
